These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35748584)

  • 1. Familial diabetes predisposes PCOS patients to insulin resistance (IR), reproductive impairment and hepatic dysfunction: effects of d-chiro inositol (DCI) and alpha lipoic acid (ALA) administration on hepatic insulin extraction (HIE) index.
    Genazzani AD; Battipaglia C; Petrillo T; Piacquadio N; Ambrosetti F; Arnesano M; Semprini E; Sponzilli A; Tomatis V; Simoncini T
    Gynecol Endocrinol; 2022 Aug; 38(8):681-688. PubMed ID: 35748584
    [No Abstract]   [Full Text] [Related]  

  • 2. Alpha lipoic acid administration improved both peripheral sensitivity to insulin and liver clearance of insulin reducing potential risk of diabetes and nonalcoholic fatty liver disease in overweight/obese PCOS patients.
    Genazzani AD; Battipaglia C; Rusce L; Prampolini G; Aio C; Ricciardiello F; Foschi M; Sponzilli A; Semprini E; Petrillo T
    Gynecol Endocrinol; 2024 Dec; 40(1):2341701. PubMed ID: 38622970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both.
    Genazzani AD; Prati A; Marchini F; Petrillo T; Napolitano A; Simoncini T
    Gynecol Endocrinol; 2019 Dec; 35(12):1088-1093. PubMed ID: 31304823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of d-chiro-inositol and alpha-lipoic acid combination on COH outcomes in overweight/obese PCOS women.
    Artini PG; Obino MER; Micelli E; Malacarne E; Vacca C; Papini F; Cela V
    Gynecol Endocrinol; 2020 Sep; 36(9):755-759. PubMed ID: 32157927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria.
    Pustotina O; Myers SH; Unfer V; Rasulova I
    Gynecol Obstet Invest; 2024; 89(2):131-139. PubMed ID: 38295772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome.
    Fruzzetti F; Capozzi A; Canu A; Lello S
    Gynecol Endocrinol; 2019 Jun; 35(6):506-510. PubMed ID: 30612488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients.
    Genazzani AD; Shefer K; Della Casa D; Prati A; Napolitano A; Manzo A; Despini G; Simoncini T
    J Endocrinol Invest; 2018 May; 41(5):583-590. PubMed ID: 29090431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients.
    Genazzani AD; Santagni S; Rattighieri E; Chierchia E; Despini G; Marini G; Prati A; Simoncini T
    Gynecol Endocrinol; 2014 Jun; 30(6):438-43. PubMed ID: 24601829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. d-chiro-Inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS.
    Cianci A; Panella M; Fichera M; Falduzzi C; Bartolo M; Caruso S
    Gynecol Endocrinol; 2015 Jun; 31(6):483-6. PubMed ID: 25893270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome.
    Baillargeon JP; Iuorno MJ; Apridonidze T; Nestler JE
    Metab Syndr Relat Disord; 2010 Apr; 8(2):127-36. PubMed ID: 20156067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role of d-
    Simic D; Nikolic Turnic T; Dimitrijevic A; Zivadinovic A; Milosevic-Stevanovic J; Djuric D; Zivkovic V; Jakovljevic V
    Can J Physiol Pharmacol; 2022 Jul; 100(7):629-636. PubMed ID: 35413205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review.
    Galazis N; Galazi M; Atiomo W
    Gynecol Endocrinol; 2011 Apr; 27(4):256-62. PubMed ID: 21142777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome.
    Baillargeon JP; Diamanti-Kandarakis E; Ostlund RE; Apridonidze T; Iuorno MJ; Nestler JE
    Diabetes Care; 2006 Feb; 29(2):300-5. PubMed ID: 16443877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.
    Genazzani AD; Prati A; Santagni S; Ricchieri F; Chierchia E; Rattighieri E; Campedelli A; Simoncini T; Artini PG
    Gynecol Endocrinol; 2012 Dec; 28(12):969-73. PubMed ID: 22612517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does Alpha-lipoic acid improve effects on polycystic ovary syndrome?
    Laganà AS; Monti N; Fedeli V; Gullo G; Bizzarri M
    Eur Rev Med Pharmacol Sci; 2022 Feb; 26(4):1241-1247. PubMed ID: 35253180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS).
    Januszewski M; Issat T; Jakimiuk AA; Santor-Zaczynska M; Jakimiuk AJ
    Ginekol Pol; 2019; 90(1):7-10. PubMed ID: 30756365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment with α-lipoic acid and myo-inositol positively affects clinical and metabolic features of polycystic ovary syndrome.
    Fruzzetti F; Fidecicchi T; Palla G; Gambacciani M
    Gynecol Endocrinol; 2020 Feb; 36(2):152-155. PubMed ID: 31317814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
    Nordio M; Proietti E
    Eur Rev Med Pharmacol Sci; 2012 May; 16(5):575-81. PubMed ID: 22774396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inositol as putative integrative treatment for PCOS.
    Genazzani AD
    Reprod Biomed Online; 2016 Dec; 33(6):770-780. PubMed ID: 27717596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study.
    La Marca A; Grisendi V; Dondi G; Sighinolfi G; Cianci A
    Gynecol Endocrinol; 2015 Jan; 31(1):52-6. PubMed ID: 25268566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.